CDK4 and breast carcinoma: Nowadays, the upfront treatment for patients facing a diagnosis of advanced luminal breast cancer (BC) is a combination of endocrine therapy (ET) with an inhibitor of CDK4/6 (CDK4/6i), which effectively targets and prevents cell cycle progression in hormone-dependent BC.